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Berberine is known to improve glucose and lipid metabolism disorders, but the mechanism is still under investigation. In this
paper, we explored the eﬀects of berberine on the weight, glucose levels, lipid metabolism, and serum insulin of KKAy mice and
investigated its possible glucose and lipid-regulating mechanism. We randomly divided KKAy mice into two groups: berberine
group (treated with 250mg/kg/d berberine) and control group. Fasting blood glucose (FBG), weight, total cholesterol (TC),
triglyceride (TG), high-density lipoprotein-cholesterol (HDL-c), low-density lipoprotein-cholesterol (LDL-c), and fasting serum
insulin were measured in both groups. The oral glucose tolerance test (OGTT) was performed. RT
2 PCR array gene expression
analysis was performed using skeletal muscle of KKAy mice. Our data demonstrated that berberine signiﬁcantly decreased
FBG, area under the curve (AUC), fasting serum insulin (FINS), homeostasis model assessment insulin resistance (HOMA-IR)
index, TC, and TG, compared with those of control group. RT
2 proﬁler PCR array analysis showed that berberine upregulated
the expression of glucose transporter 4 (GLUT4), mitogen-activated protein kinase 14 (MAPK14), MAPK8(c-jun N-terminal
kinase, JNK), peroxisome proliferator-activated receptor α (PPARα), uncoupling protein 2 (UCP2), and hepatic nuclear factor
4α(HNF4α), whereas it downregulated the expression of PPARγ, CCAAT/enhancer-binding protein (CEBP), PPARγ coactivator
1α(PGC 1α), and resistin. These results suggest that berberine moderates glucose and lipid metabolism through a multipathway
mechanism that includes AMP-activated protein kinase-(AMPK-) p38 MAPK-GLUT4, JNK pathway, and PPARα pathway.
1.Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder
characterized by dysregulation of carbohydrate, protein, and
fat metabolism resulting from defects in insulin secretion,
insulin action, or both [1]. The number of T2DM patients
is expected to rise to 300 million worldwide by the year
2025 due to an increased number of elderly people, a greater
prevalence of obesity, and sedentary lifestyles [2]. Besides
hyperglycemia, several other symptoms, including hyperlipi-
demia, are involved in the development of microvascular
and macrovascular complications of diabetes, which are
the major causes of morbidity and death. Therefore, it is
especially important to reinforce eﬀective prevention and
regular treatment of this disease. However, since patient
compliance with diet and exercise regiments is often poor
and medications are needed and because many oral medica-
tions have a number of serious adverse eﬀects, management
of hyperglycemia or hyperlipidemia with low side eﬀects
remains a challenge to the medical system. Traditional
Chinese medicines and their extractions demonstrate the
characteristics of economy and eﬀectiveness in managing
diabetes and its complications.
Rhizoma Coptidis was recorded as an antidiabetes med-
ication about 1500 years ago in a book titled “Note of
Elite Physicians” by Hongjing Tao. Berberine is the major
active component of Rhizoma coptidis. Recent studies have
demonstrated beneﬁcial eﬀects of berberine on metabolism
disorders including weight control, cholesterol reduction,
antilipogenic and hypoglycemic eﬀects, and even inhibiting
chronic cocanine-induced sensitization [3–6].
Many studies have been published on the glucose-
reducing mechanism of berberine. Zhou et al. found
that berberine stimulated glucose transport through a
mechanism distinct from insulin in 3T3-L1 adipocyes [7].
Moreover, berberine could activate AMPK and induced gly-
colysisinL6,C2C12,and3T3-L1celllines[8].Andberberine
dose-dependently inhibited respiration in L6 myotubes by2 Evidence-Based Complementary and Alternative Medicine
its speciﬁc eﬀect on respiratory complex I [9]. Regarding the
mechanism of berberine in moderating lipid metabolism,
Leeetal.foundthatberberinemoderatedlipidsbyinhibiting
adipogenesis in 3T3-L1 adipocytes [10]. Two trials revealed
that berberine activated extracellular signal-regulated kinase
(ERK) [7]a n dJ N K[ 11] in HepG2 cells. Given these results,
we hypothesize that berberine may exhibit a multitargeted
mechanism in moderating glucose and lipids.
Trial materials used in biomedical studies often involve
cells. However, in this study, KKAy mice were used
to investigate the eﬀects of berberine on glucose and lipid
metabolisminvivo.KKAymicearedevelopedbytransferring
the yellow obesity (Ay) gene into the KK strain, which show
severeobesity,hyperglycemia,hyperinsulinemia,andglucose
intolerance by eight weeks of age. So, they are especially
useful for evaluating of antidiabetic and antiobesity agents.
The skeletal muscle plays a major role in energy balance. It
accounts for >30% of energy expenditure and is the primary
tissue of insulin stimulating glucose uptake, disposal, and
storage [12]. To understand the mechanism that berberine
regulates glucose and lipids, we performed RT2 PCR diabetes
superarraytoanalyzetheexpressionofdiabetes-relatedgenes
in skeletal muscle tissue of KKAy mice. Natural products
are gaining increased applications in drug discovery and
development. Being chemically diverse, they are able to
modulate several targets simultaneously in a complex
system. DNA microarrays serve as suitable high-throughput
tool for simultaneous analysis of multiple genes [13].
2.MaterialsandMethods
2.1. Animal Modeling, Grouping, and Treatment. Male KKAy
mice (from the Chinese Academy of Medical Sciences,
Beijing, China) were fed in the standard mouse-feeding
room. The mice were fed with high-fat laboratory chow
(fat: carbohydrate:p r o t e i n= 58:25.6:16.4). All procedures
were approved by the Ethics Committee for the Use of
Experimental Animals of Peking Union Medical College
Hospital. Before drug administration, murine blood samples
for blood glucose measurement were collected from the tail
vein. KKAy mice with random blood glucose values above
11.1mmol/L were considered diabetic. These mice were
randomly divided into two groups: berberine group (n = 8,
ig 250mg·kg−1·d−1 berberine) and control group (n = 8,
ig the same volume of normal saline). Drugs were given
to the mice between 8:00 and 9:00 AM every day. Over a
four-week period, on days 0 (before treatment), 7, 14, 21,
and 28, weight and FBG of the KKAy mice (4-hour fast) were
measured in blood samples obtained from tail veins. An oral
glucose tolerance test (OGTT) was performed on day 21. On
day 28, blood samples of the KKAy mice were again taken
for measuring FINS and lipid metabolic parameters, after
anesthesia. The mice were then sacriﬁced and their skeletal
muscles were collected and stored in dry ice.
2.2. Oral Glucose Tolerance Test (OGTT). After the mice
fasted for 4 hours, glucose 2.2g/kg was orally administered.
Then blood samples were collected from tail veins at 0 (prior
to glucose load), 30, 60, and 120 minutes (after glucose load)
for the glucose assay. AUC was calculated for blood glucose
(BG) during the OGTT: AUC = 0.5 × [Bg0 + Bg30]/2 + 0.5
× [Bg30 + Bg60]/2 + 1 × [Bg60 + Bg120]/2.
2.3. Measurement of Serum Parameters. Blood glucose was
measured by the glucose oxidase peroxidase (Bayer Breeze
blood glucose meter, Germany) method. TC, TG, LDL-c,
and HDL-c were assayed by enzyme end-point method
(Roche, Germany). Serum insulin was measured by enzyme-
linked immunosorbent assay (ELISA) using rat/mice insulin
ELISA kit (LINCO Research, USA). HOMA-IR index was
calculated according to the following formula: HOMA-IR =
FBG (mmol/L) × FINS (μU/mL)/22.5.
2.4. RT2 Proﬁler PCR Array
2.4.1. First Strand cDNA Synthesis. Total RNA was extracted
from the skeletal muscle of 3 mice from the berberine
group and 3 mice from the control group, using TRIZOL
Reagent (Invitrogen Life Technologies, USA). RNA cleanup
used RNeasy MinElute Cleanup Kit (Qiagen, Germany).
RNA quality was determined by running a sample with
RNA loading dye (Ambion, USA) on a 1% agarose gel and
inspecting for distinct 18S and 28S bands, indicating lack of
degradation. Quantity was determined by A260 and A280
measurement. All samples had A260/A280 ratios of 1.9−2.1.
SuperScript Reverse Transcriptase was applied to reverse-
transcribe RNA into ﬁrst-strand cDNA. To analyze the
diﬀerential expression of multiple genes involved in diabetes
mellitus, we used RT2 proﬁler PCR mouse diabetes mellitus-
speciﬁcexpressionarrays(SuperArray,Frederick,MA,USA),
which uses SYBR Green-based real-time PCR to assay a large
numberofgenessimultaneously.Eachsuperarraymembrane
contained 84 speciﬁc cDNA fragments of genes involved
in diabetes mellitus, including receptors, transporters and
channels,nuclearreceptors,metabolicenzymes,secretedfac-
tors, transcription factors, and others. Table 1 lists the genes
m e a s u r e di nt h i ss t u d y .W ea d d e dc D N At oe a c hw e l lo fa n
RT2 proﬁler PCR diabetes array for quantitative PCR in the
ABIPRISM7700system(AppliedBiosystems,USA)withthe
following cycling conditions: an initial denaturation at 95◦C
15 minutes, and 40 cycles of 95◦C 15 seconds, 55◦C6 0s e c -
onds, with a ﬁnal inﬁnite 4◦C hold. Fluorescence signal was
then collected. For quality control purpose, no reverse tran-
scription control and no template control were performed.
2.4.2. Data Normalization and Analysis. Five endogenous
control genes—glucuronidase β(GUS β), hypoxanthine gua-
nine (HPRT1), heat-shock protein (HSP90), glyceralse-
hyde(GAPDH), and β-actin(ACT β)—present on the PCR
Array were used for normalization. Each replicate cycle
threshold (Ct) was normalized to the average Ct of 5
endogenous controls on a per plate basis. The comparative
Ctmethodwasusedtocalculatetherelative quantiﬁcationof
gene expression. The following formula was used to calculate
the relative amount of the transcripts in the berberine-
treated samples and samples of the control group, both ofEvidence-Based Complementary and Alternative Medicine 3
Table 1: Gene list of RT2 proﬁler PCR mouse diabetes array.
Ace Acly Adra1a Adrb3 Agt Akt2 Aqp2 Ccl5 Ccr2 Cd28 Ceacam1 Cebpa
Ctla4 Dpp4 Dusp4 Enpp1 Fbp1 Foxc2 Foxg1 Foxp3 G6pc G6pd2 Gcg Gcgr
Glp1r Gpd1 Gsk3b Hmox1 Hnf4a Icam1 Ide Ifng Igfbp5 Ikbkb Il10 Il12b
Il4ra Il6 Inppl1 Ins1 Pdx1 Irs1 Mapk14 Mapk8 Neurod1 Nfkb1 Nos3 Nrf1
Nsf Parp1 Pax4 Pck1 Pfkfb3 Pik3cd Pik3r1 Ppara Pparg Ppargc1a Ptpn1 Pygl
Rab4a Retn Sell Serpine1 Slc14a2 Slc2a4 Snap23 Snap25 Sod2 Srebf1 Stx4a Stxbp1
Stxbp4 Hnf1b Tgfb1 Tnf Tnfrsf1a Tnfrsf1b Trib3 Ucp2 Vamp2 Vamp3 Vapa Vegfa
Gusb Hprt1 Hsp90ab1 Gapdh Actb MGDC RTC RTC RTC PPC PPC PPC
Table 2: Eﬀect of berberine on the body weight and FBG of KKAy mice.
Group n Day 0 Day 7 Day 14 Day 21 Day 28
Control
Weight (g) 8 30.51 ± 2.44 31.92 ± 3.28 32.21 ± 3.15 32.90 ± 1.34 33.04 ± 1.42
FBG (mmol/L) 8 16.15 ± 8.98 19.60 ± 2.15 18.28 ± 5.05 24.74 ± 8.89 20.54 ± 5.85
Berberine
Weight (g) 8 30.08 ± 1.94 30.86 ± 1.08 31.04 ± 1.76 31.55 ± 1.17 31.88 ± 0.74
FBG (mmol/L) 8 16.45 ± 8.04 9.90 ± 5.69∗ 10.35 ± 4.14∗ 10.20 ± 2.48∗∗ 9.90 ± 2.95∗∗
Values are means ± SD.
∗Indicates signiﬁcantly diﬀerent versus control (P<. 05); ∗∗(P<. 01).
which were normalized to the endogenous controls. ΔΔCt
= ΔCt (berberine group)—ΔCt (control group) for RNA
samples [14]. ΔCt is the log2 diﬀerence in Ct between
the target gene and endogenous controls abstained by
subtracting the average Ct of controls from each replicate.
The fold change for each berberine-treated sample relative to
the control sample = 2−ΔΔCt.
2.4.3. Sensitivity Detection and Identiﬁcation Expressed Genes.
PCR Array quantiﬁcation was based on the Ct number. Ct
was deﬁned as 35 for the ΔCt calculation when the signal
was under detectable limits. A list of diﬀerentially expressed
genes was identiﬁed using a 2-tailed t-test. Changes in gene
expression between the berberine group and the control
groupwereillustratedasafoldincrease/decrease.Thecriteria
were a P value <.05 and a mean diﬀerence equal to or greater
than 2-fold. The statistical calculation was based on the web-
based program of RT2 proﬁler PCR Array Data Analysis.
Genes that suited the above criteria were considered to be
up- or downregulated. The experiments were repeated three
times.
2.5. Statistical Analysis. All results are expressed as means
± SD. The statistical value of P<. 05 was considered
as statistical signiﬁcance. Diﬀerences between the berberine
group and the control group were determined using the
Mann-Whitey U test. All statistical analyses were performed
with SPSS version 12.0 software.
3. Results
3.1. Berberine Showed no Eﬀe c to nB o d yW e i g h to fK K A y
Mice. No signiﬁcant diﬀerences were noted between the
initial body weight of KKAy mice in the berberine group
and the control group. Also, after treatment, no signiﬁcant
diﬀerences were found between groups, suggesting that
berberine does not aﬀect body weight (Table 2, Figure 1(a)).
3.2. Berberine Decreased FBG of KKAy Mice. Before drug
administration, FBG in both groups was similar. However,
the FBG in the berberine group displayed a signiﬁcant
decrease on day 7 (P<. 05), day 14 (P<. 05), day 21
(P<. 01), and day 28 (P<. 01) (Table 2, Figure 1(b)). This
showed that administration of berberine reduced the FBG of
KKAy mice.
3.3. Berberine Improved the Glucose Tolerance of KKAy Mice.
Blood glucose levels in two groups became elevated within
30 minutes after the administration of glucose to mice.
Blood glucose levels recovered to the original levels after
120 minutes. The blood glucose level in mice treated with
berberine was signiﬁcantly suppressed at 0 minutes (P<
.01), 30 minutes (P<. 01), 60 minutes (P<. 05), and
120 minutes (P<. 05) compared to those in the control
group (Table 3, Figure 2) .A U Ci nt h eb e r b e r i n eg r o u pw a s
signiﬁcantly smaller than that in the control group (P<
.05) (Table 3, Figure 3(a)). This indicated that berberine
improved the glucose tolerance of KKAy mice.
3.4. Berberine Reduced FINS and HOMA-IR in KKAy Mice.
The mice fed with berberine exhibited signiﬁcantly lower
fasting serum insulin levels than the control group (P<. 05)
(Table 4, Figure 3(b)).The HOMA-IR index of the berberine
group was 30% of that of the control group (P<. 05)
(Table 4, Figure 3(c)).These data showed that berberine
ameliorated the insulin sensitivity of KKAy mice.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Weekly variation of body weight (a) and fasting blood
glucose (b) between berberine group and control group. Data are
expressed as means ± SD.
∗P <. 05,
∗∗P <. 01 compared with that
in the control.
3.5.BerberineDeclinedTCandTGinKKAyMice. Inaddition
to its glucose-lowering eﬀects, berberine may have lipid-
regulating activity. After 4 weeks of treatment, the animals
fedwithberberineexhibitedasigniﬁcantdecreaseinTC(P<
.05) and TG level (P<. 05). However, diﬀerences in HDL-
c and LDL-c between the two groups were not statistically
signiﬁcant (Table 4, Figure 3(d)).
3.6. RT2 Proﬁler PCR Array. Based on the results of the RT2
proﬁler PCR array, we found no signiﬁcantly diﬀerent genes
expression between berberine and control group related to
the insulin signaling pathway. For example, gene expression
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Figure 2: Comparison of plasma glucose concentration responses
to an oral glucose tolerance test between berberine group and
control group. Data are expressed as means ± SD.
∗P <. 05,
∗∗P <. 01 compared with that in the control.
of thymoma viral proto-oncogene 2(AKT2), inhibitor of
kappaBkinaseβ (IKBKB),insulinreceptorsubstrate(IRS-1),
phosphatidlyinositol-3 kinase regulatory subunit polypep-
tide 1 (PIK3R1), phosphatidylinositol 3-kinase catalytic δ
polypeptide (PIK3CD), and protein tyrosine phosphatase
nonreceptortype1(PTPN1,PTP1B),allofwhichareinvolved
in the insulin signaling pathway, were not markedly upregu-
lated or downregulated.
Based on gene selection criteria (P<. 05 and fold
change ≥2), 10 genes that were ≥2-fold upregulated or
downregulated in the berberine group as shown in Table 5
and Figure 4.
According to the gene expression proﬁle, we found that
berberinecouldupregulatedtheexpressionof2genesrelated
to the MAPK (mitogen-activated protein kinase) pathway.
For example, gene expression of MAPK8 and MAPK14,
both of which are involved in the MAPK pathway, was
upregulated(13.15-foldand4.17-fold,resp.)intheberberine
group. Also, glucose transporter 4 (GLUT4) gene expression,
which is involved in glucose transport in membranes, was
upregulated by 4.48-fold in the berberine group. Gene
expression of peroxisome proliferator-activated receptor γ
(PPARγ), CCAAT/enhancer-binding protein (CEBP), and
PPARγ coactivator 1α (PGC), which play important roles
in adipogenesis, were downregulated (5.51-fold, 3.06-fold,
and 2.70-fold, resp.). PPARα gene expression, which leads
to reduction of plasma TG levels, was upregulated by 2.10-
fold in the berberine group. In addition, gene expression
of uncoupling protein 2 (UCP2), whose expression is
involved in energy balance, was upregulated by 2.55-fold
in the berberine group. Furthermore, expression of hepatic
nuclear factor 4α(HNF-4α) gene, a key regulator of glucose,
cholesterol, and fatty acid metabolism, was upregulated by
2.12-fold in the berberine group. Gene expression of resistin,
which contributes to insulin resistance, was downregulated
by 2.12-fold in the berberine group.Evidence-Based Complementary and Alternative Medicine 5
50
40
30
20
10
0
∗
A
r
e
a
u
n
d
e
r
t
h
e
c
u
r
v
e
(
m
m
o
l
/
L
)
(a)
F
a
s
t
i
n
g
i
n
s
u
l
i
n
(
μ
U
/
m
L
)
0
20
15
10
5
25
∗
(b)
∗
H
O
M
A
-
I
R
15
10
5
0
Control
Berberine
(c)
∗
∗
Control
Berberine
L
i
p
i
d
m
e
t
a
b
o
l
i
c
p
a
r
a
m
e
t
e
r
s
(
m
m
o
l
/
L
)
0
2
4
6
TC TG HDL-C LDL-C
(d)
Figure 3: Area under the curve in OGTT trial (a), serum concentration of fasting insulin (b), HOMA-IR, (c) and lipid metabolic parameters
(d) between berberine group and control group. Data are expressed as means ± SD.
∗P <. 05 compared with that in the control.
4. Discussion
In this study, we found that the administration of berberine
to KKAy mice signiﬁcantly reduced FBG levels, FINS, and
HOMA-IR index. Our results suggest that berberine has
glucose-moderating action and can ameliorate oral glucose
tolerance and insulin sensitivity. This result is similar to the
results of other studies [7, 8, 10, 15–17]. However, Lee et al.
treated ob/ob mice with berberine for 25 days and found
that berberine could reduce the body weight [10]. In our
study, berberine did not reduce body weight signiﬁcantly.
Othermore, berberine decreased serum TG and TC levels in
KKAy mice. Two groups revealed the similar results [18, 19].
However, Kong et al. found that oral administration of
berberine in 32 hypercholesterolemic patients for 3 months
reduced LDL-cholesterol by 25% [19]. While in this study,
we found no evidence that berberine reduces serum LDL-c.
The mechanism of the hypoglycemic action of berberine
is still under investigation. Our gene expression proﬁle
results showed no signiﬁcant diﬀerences in gene expression
between the berberine and the control group related to the
insulin signaling pathway, including AKT2, IKBKB, IRS-
1, PIK3R1, PIK3CD, and PTPN1 (PTP1B). In the insulin
signaling pathway, insulin stimulates glucose uptake to mus-
cle and fat tissue [20]. It involves certain signal molecules,
such as insulin receptor (IR), IRS-1, phosphatidylinositol 3-
kinase (PI3K), and AKT. Defects are found in the insulin
signaling pathway in muscle tissue of T2DM. Based on our6 Evidence-Based Complementary and Alternative Medicine
results, we do not consider the insulin signaling pathway
to be the key mechanism of the glucose-moderating eﬀect
of berberine. Other research supports this view. Berberine
only weakly stimulated the phosphorylation of AKT/PKB
[21] and did not augment tyrosine phosphorylation of IR
and IRS-1 in 3T3-L1 cells [22]. Unlike insulin, the eﬀect
of berberine on increasing glucose uptake was insensitive
to wortmannin, an inhibitor of PI3K, and SB203580, an
inhibitor of p38 MAPK [7]. IKBKB can phosphorylate
IRS1 on Ser307, thereby rendering IRS1 less amenable to
become phosphorylated on tyrosine residues required to
propagate the signal to downstream eﬀectors such as protein
kinase B [23]. PTP1B may dephosphorylate IRS-1 [24, 25].
Other studies suggest that PTP1B polymorphisms may be
associatedwithobesityandinsulinresistanceinhumans[26–
28] .T h eo v e r e x p r e s s i o no fP T P 1 Bi nm u s c l et i s s u er e s u l t si n
insulin resistance [29].
We disclosed that berberine could upregulate the expres-
sion of 2 genes related to MAPK (mitogen-activated protein
kinase) pathway and GLUT4. This suggests that berberine
can activates MAPK in KKAy mice. The p38 MAPK cascade
is downstream of AMPK in the signaling pathway of AICAR-
stimulated glucose transport in Clone 9 cells [30, 31]. In
muscle tissue, p38 MAPK takes part in the activation of
GLUT4 [30, 32]. It is possible that berberine can amelio-
rate glucose uptake in T2DM mice through the AMPK-
p38 MAPK-GLUT4 pathway. The possibility that berberine
activate MAPK is still under investigation. Cheng et al. found
that berberine strongly promotes the phosphorylation of
AMPKandp38MAPKonL6ratskeletalmuscles[21].More-
over, berberine-stimulated glucose uptake was inhibited by
the AMPK inhibitor Compound C and the p38 MAPK
inhibitorSB202190.InhibitionofAMPKreducedp38MAPK
phosphorylation, suggesting that AMPK lies upstream of
p38 MAPK. These results suggest that berberine circumvents
insulin signaling pathways and stimulates glucose uptake
through the AMP-AMPK-p38 MAPK pathway, which may
account for the antihyperglycemic eﬀects of this drug [21].
Zhou et al. found that in isolated rat skeletal muscles,
metformin stimulates glucose uptake coincident with AMPK
activation [33]. However, Lee et al. revealed that berberine
increasedAMPKphosphorylation,butitdidnotactivatep38
[10] .S e v e r a lg r o u p si n v e s t i g a t e dt h ee ﬀect of berberine on
glucose transporters and their conclusions remain contro-
versial. Two groups also reported that berberine was able to
stimulate GLUT4 translocation [10, 34], but this activity was
not observed by other groups [10, 22]. Repeated intravenous
administration of tetrandrine (1.0mg/kg) to STZ-diabetic
rats for 3 days resulted in an increase in the mRNA and
protein levels of the GLUT4 in soleus muscle, in addition to
the lowering of plasma glucose [35].
Although, the exact mechanisms of berberine lipid-
modulating eﬀects are still unknown, we found that berber-
ine could downregulate PPARγ, PGC-1, and C/EBPα and
upregulate PPARα.T h en u c l e a rr e c e p t o rP P A R γ and mem-
bersoftheC/EBPfamilytakeimportantrolesinadipogenesis
[36]. The expression of both gluconeogenic and β-oxidation
genes is further potentiated by the nuclear hormone receptor
coactivator PGC-1, a target of cyclic AMP (cAMP) response
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Figure 4: The Volcano Plot graphs of superarray. This graph shows
that the log2 of the fold change in each gene’s expression between
berberine group and control group is versus its P value from the
t-test. The black line indicates fold changes of 1. The pink lines
indicate that the fold change in gene expression threshold is 2. The
blue line indicates that the P value of the t-test threshold is .05.
Therewere10geneswhichshowedsigniﬁcantlydiﬀerentexpression
between berberine group and control group.
element binding (CREB), whose levels are increased during
fasting and in diabetes [37, 38]. Berberine could downreg-
ulate the expression of PPARγ, PGC-1, and C/EBP levels,
which may be the mechanism that prevented KKAy mice
treated with berberine from gaining weight. Weight gain
has been identiﬁed as a class eﬀect of the thiazolidinediones
(TZDs). A factor contributing to TZD-related weight gain is
increased adipocyte diﬀerentiation. The antidiabetic eﬀects
ofTZDsaremediated throughPPARγ,a positive regulatorof
adipocyte diﬀerentiation [39]. Activation of PPARγ triggers
the production of smaller more insulin-sensitive adipocytes,
predominantly in the subcutaneous adipose compartment,
and is likely to contribute to the TZD-mediated weight gain
that has been observed in both animal and human studies
[40]. Obesity is a major risk factor for metabolic syndrome
and T2DM. However, most antidiabetic drugs that are hypo-
glycemic also promote weight gain, alleviating one symptom
of T2DM while aggravating a major risk factor that leads
to T2DM. It is highly desirable to develop pharmaceuticals
and treatments for T2DM that reduce blood glucose levels
without inducing adipogenesis in patients. Many studies
have showed that berberine inhibited the mRNA and protein
levels of adipogenesis-related transcription factors PPARγ
and C/EBPα [10, 41, 42]. Two groups conﬁrmed that berber-
ineincreasedPPARα/δ expressioninliverandskeletalmuscle
tissue of diabetic rats [43, 44]. PPARα governs the expression
of numerous genes involved in a variety of metabolic pro-
cessesandmodulateslipoproteinmetabolisminseveralways.Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: The mechanism of berberine moderating glucose and lipid metabolism.
Table 3: Eﬀect of berberine on oral glucose tolerance in KKAy mice (mmol·L−1).
Group n BG 0min BG 30min BG 60min BG 120min AUC
Control 8 24.74 ± 8.89 29.90 ± 4.98 22.10 ± 10.67 17.70 ± 8.29 45.45 ± 10.81
Berberine 8 10.20 ± 2.48∗∗ 20.58 ± 7.69∗∗ 14.90 ± 6.69∗ 11.08 ± 6.36∗ 29.90 ± 11.89∗
Values are means ± SD.
∗Indicates signiﬁcantly diﬀerent versus control (P<. 05); ∗∗(P<. 01).
Table 4: Eﬀect of berberine on FINS, HOMA-IR, and lipid metabolic parameters in KKAy mice.
Group n FINS (μU/mL) HOMA-IR TC (mmol/L) TG (mmol/L) HDL-c (mmol/L) LDL-c (mmol/L)
Control 8 17.15 ± 7.74 13.45 ± 5.07 5.20 ± 1.93 1.29 ± 0.40 3.66 ± 0.95 0.86 ± 0.20
Berberine 8 6.80 ± 3.36∗ 3.05 ± 1.45∗ 3.03 ± 0.69∗ 0.75 ± 0.25∗ 4.00 ± 1.12 0.80 ± 0.12
Values are means ± SD.
∗Indicates signiﬁcantly diﬀerent versus control (P<0.05).
Table 5: The genes that expressed diﬀerently between berberine group and control group (fold change 2.0, P<. 05).
Gene name Description GeneBank ID Fold change P value t-test
SLC2A4 Solute carrier family 2(GLUT4) NM 009204 4.48 .0081
MAPK8 Mitogen-activated protein kinase 8(JNK) NM 016700 13.15 .0203
MAPK14 Mitogen-activated protein kinase 14 NM 011951 4.17 .0171
PPARα Peroxisome proliferator-activated receptor alpha NM 011144 2.10 .0316
PPARγ Peroxisome proliferator-activated receptor gamma NM 011146 −5.51 .0412
CEBP CCAAT/enhancer-binding protein, alpha NM 011144 −3.06 .0385
PPARγC1α Peroxisome proliferative-activated receptor, gamma,
coactivator 1 alpha(PGC)
NM 008904 −2.70 .0306
UCP2 Uncoupling protein 2 NM 011671 2.55 .0480
RETN RESISTIN NM 022984 −2.12 .0059
HNF4α Hepatic nuclear factor 4, alpha NM 008261 2.12 .04558 Evidence-Based Complementary and Alternative Medicine
Activation of PPARα results in a reduction of plasma TG
levels, which is achieved by induction of genes that decrease
the availability of TG for hepatic VLDL secretion and
induction of genes that promote lipoprotein lipase-mediated
lipolysis of TG-rich plasma lipoproteins [45]. Upregulation
of PPARα may be the mechanism of the action of berberine
in moderating lipid metabolism, just as in ﬁbrate.
We also found that berberine could upregulate MAPK8
(JNK1). Berberine could increase the transcriptional activity
of LDLR promoter and it involved the JNK pathway,
reducing serum LDL [11]. Oral administration of berberine
in 32 hypercholesterolemic patients for 3 months reduced
serum cholesterol by 29%, triglycerides by 35%, and LDL-
cholesterol by 25% [19]. Treatment of hyperlipidemic ham-
sters with berberine reduced serum cholesterol by 40%
and LDL-cholesterol by 42%, with a 3.5-fold increase in
hepatic LDLR mRNA, and a 2.6-fold increase in hepatic
LDLR protein [19]. Using human hepatoma cells, berber-
ine upregulated LDLR expression independent of sterol
regulatory element binding proteins but was dependent
on ERK activation [46]. Although we found no evidence
that berberine can reduce serum LDL, the upregulation of
MAPK is a possible factor in the berberine lipid-regulating
mechanism.
Moreover, berberine could upregulate UCP2. UCP2,
which is found in many tissues, aﬀects body weight gain,
resting metabolic rates and food intake, which are all
involved in energy balance [47]. In adipocytes and skeletal
muscletissue,UCP2expressionappearstoincreasefollowing
high-fat feeding. An increase in UCP2 levels might be
expected to increase energy expenditure and decrease the
risk of obesity. In skeletal muscle, the expression of UCP2
mRNA was signiﬁcantly increased by berberine [10]. We
speculated that bererine could upregulate UCP2, increase
energy dissipation, and decrease the risk of obesity.
Also, we revealed that berberine could downregulate
resistin. Resistin, as an adipocyte-secreted factor (ADSF), is a
mouse protein with potential roles in insulin resistance and
adipocyte diﬀerentiation. The TZD drug rosiglitazone can
reduceresistinexpressiontoimproveinsulinresistance.Ding
et al. found that the eﬀects of berberine in moderating lipids,
as well as its contribution to reducing leptin and resistin,
were closely correlated with its eﬀects in ameliorating insulin
resistance [48].
Additionally, berberine upregulated hepatic nuclear fac-
tor 4α(HNF4α). HNF4α is a key regulator of a number
of genes involved in glucose, cholesterol, and fatty acid
metabolism [49]. The mRNA and protein expression of
HNF-4α were decreased in fructose-fed rats, but berber-
ine promoted its expression [50]. Figure 5 shows the
mechanism of berberine in moderating glucose and lipid
metabolism.
In summary, our studies provide evidence that berberine
reduces FBG and FINS and ameliorates insulin sensitivity
and secretion in KKAy mice. Moreover, berberine reduces
serum TC and TG and thereby regulates lipid metabolism.
Berberine, in our study and others, caused changes in the
expression of many genes that are involved in AMPK-
p38 MAPK-GLUT4, JNK pathway, and PPARα pathway.
These results provide molecular information for further
investigation of the mechanisms by which berberine mod-
erates glucose and lipid metabolism. Furthermore, these
results could be important in devising mechanism-based
and targeted therapeutic strategies for diabetes and lipid
disorders. Further studies (i.e., real-time quantitative PCR)
are planned to validate the gene expression proﬁle changes
observed with the RT2 Proﬁler PCR array.
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